IL84275A - Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders - Google Patents

Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders

Info

Publication number
IL84275A
IL84275A IL84275A IL8427587A IL84275A IL 84275 A IL84275 A IL 84275A IL 84275 A IL84275 A IL 84275A IL 8427587 A IL8427587 A IL 8427587A IL 84275 A IL84275 A IL 84275A
Authority
IL
Israel
Prior art keywords
erythropoietin
treatment
pharmaceutical composition
iron overload
iron
Prior art date
Application number
IL84275A
Other languages
English (en)
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of IL84275A publication Critical patent/IL84275A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Manufacture Of Iron (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Iron (AREA)
  • Hydrogen, Water And Hydrids (AREA)
IL84275A 1986-11-21 1987-10-25 Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders IL84275A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/933,495 US5013718A (en) 1986-11-21 1986-11-21 Method for treating iron overload using EPO

Publications (1)

Publication Number Publication Date
IL84275A true IL84275A (en) 1993-04-04

Family

ID=25464076

Family Applications (1)

Application Number Title Priority Date Filing Date
IL84275A IL84275A (en) 1986-11-21 1987-10-25 Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders

Country Status (16)

Country Link
US (1) US5013718A (da)
EP (1) EP0269394B1 (da)
JP (1) JPH0692316B2 (da)
KR (1) KR950009100B1 (da)
AT (1) ATE68352T1 (da)
AU (1) AU602028B2 (da)
CA (1) CA1322165C (da)
DE (1) DE3773852D1 (da)
DK (1) DK167650B1 (da)
ES (1) ES2039252T3 (da)
GR (1) GR3003254T3 (da)
IE (1) IE60865B1 (da)
IL (1) IL84275A (da)
NZ (1) NZ222432A (da)
PT (1) PT86187B (da)
WO (1) WO1988003808A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880012235A (ko) * 1987-04-10 1988-11-26 벤자민 에프.람버트 정상 포유동물의 헤마토크릿을 증가시키는 방법
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1996014081A1 (en) * 1994-11-03 1996-05-17 Boehringer Mannheim Gmbh Use of erythropoietin in the treatment of rheumatoid arthritis
WO1996030068A1 (en) 1995-03-31 1996-10-03 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2001035095A2 (en) * 1999-11-12 2001-05-17 Rothenberg Barry E Diagnostic test for hemochromatosis
US7160855B2 (en) * 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
US10694961B2 (en) 2011-06-13 2020-06-30 Cedaris-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
US10694962B2 (en) 2011-06-13 2020-06-30 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
FR3037592B1 (fr) 2015-06-18 2017-06-09 Michelin & Cie Pneumatique pourvu d'une bande de roulement comprenant un elastomere dienique et un systeme d'elastomeres thermoplastiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification

Also Published As

Publication number Publication date
DE3773852D1 (de) 1991-11-21
ES2039252T3 (es) 1993-09-16
IE873113L (en) 1988-05-21
DK167650B1 (da) 1993-12-06
ATE68352T1 (de) 1991-11-15
EP0269394B1 (en) 1991-10-16
WO1988003808A1 (en) 1988-06-02
US5013718A (en) 1991-05-07
PT86187A (en) 1987-12-01
IE60865B1 (en) 1994-08-24
DK407488D0 (da) 1988-07-21
DK407488A (da) 1988-07-21
EP0269394A2 (en) 1988-06-01
NZ222432A (en) 1990-07-26
GR3003254T3 (en) 1993-02-17
KR950009100B1 (ko) 1995-08-14
AU602028B2 (en) 1990-09-27
KR890700032A (ko) 1989-03-02
PT86187B (pt) 1990-11-07
EP0269394A3 (en) 1988-09-14
JPS63159322A (ja) 1988-07-02
CA1322165C (en) 1993-09-14
AU8179487A (en) 1988-06-16
JPH0692316B2 (ja) 1994-11-16

Similar Documents

Publication Publication Date Title
IL84275A (en) Pharmaceutical composition comprising erythropoietin for treatment of iron overload disorders
ES2007341A6 (es) Un procedimiento para producir m-csf
EP0177137A3 (en) White blood cell differentiation composition and method
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
AU598020B2 (en) Cosmetic composition
PT82619A (en) Process for the preparation of a therapeutic composition for the local treatment of dandruff seborrrheic dermatitis and psoriasis
IE791001L (en) Acyl-carnitines with triglycerides
PT87197A (pt) Processo para preparacao de agentes terapeuticos eritropoietina
PH23901A (en) Treatment of diabetes using fluoxetine
EP0388799A3 (en) Use of human interferon-beta for stimulation of erythropoieses
EP0306191A3 (en) 2,3-dihydroergolines for serotonergic function enhancement
EP0259564A3 (en) A thymus derivative active after oral administration, methods of preparation and pharmaceutical compositions
OA09455A (fr) Nouveaux polyols furanniques, utilisation de ceux-ci comme polyols dans la formation de polyuréthannes, polyuréthannes ainsi obtenus et leur procédé de préparation.
IE820151L (en) Treating shock using meptazinol
ES8706110A1 (es) Un procedimiento para la preparacion de derivados de alfa-aminoalquil-alfa-alquilfenilacetonitrilo.
IE831399L (en) Pharmaceutical composition containing meptazinol and¹ibuprofen.
PT80214A (en) Process for the preparation of a pharmaceutical composition containing 9alpha,11beta-dichloro 16alpha-methyl 21-oxycarbonyldicyclohexyl-methyloxi-pregne-1,4-diene 3,20-dione as active agent and an inert product as excipient appropriate to permit r said composition to be used in the rectum or colon
EP0202778A3 (en) Use of (S)-2-amino-5-hydroxy-4-oxopentanoic acid for the preparation of a medicament for the treatment of systemic mycosis
JPS6442470A (en) Guanidinecarboxylic acid esters, manufacture and medicinal composition
FR2616430B1 (fr) Nouveaux diesters de l'acide azelaique, leur procede de preparation, les compositions topiques les contenant et leur utilisation dans le traitement de l'acne
HUT45897A (en) Process for production of medicines with big acid-fixing capacity, prolonged in time effect, increased bioutilty, neutralizing gastric acid
ES428172A1 (es) Un procedimiento para preparar acido 5-pivaloiloxi-5-(1-fe-niletil)-barbiturico.
UA7216A1 (uk) Спосіб одержання похідних 12-аміно-пірідазіно[4', 5':3,4]-пірроло[2,1-а] ізохіноліна або їх фізіологічно переносимих кислотно-аддітивних солей
CS912787A1 (en) Method of medicament preparation that contains purified gamma-globulin with high content of monomer
MA19564A1 (fr) Derives de la pyrrolidine, sa preparation et ses utilisations therapeutiques pour le traitement de l'insuffisance cerebrale

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired